• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to secondary sidebar

OINDPnews


H&T Presspart Low GWP Banner
  • Home
  • News
    • Business
    • Features
    • Medical
    • Regulatory
    • Products and Services
    • People
  • Events
  • Suppliers
    • Supplier listing and advertising options
    • Capsules and blisters
    • Consultants
    • Contract research
    • Contract manufacturing
    • Devices
    • Education
    • Excipients
      • Clinical Technology
    • Filling equipment
    • Instruments
    • Particle manufacturing
    • Software and modeling
  • Jobs
  • Resources
    • Webinars
    • White papers
  • LGWP Propellants
    • HFA 152a
    • HFO-1234ze(E)
    • LGWP Regulation
  • Contact

Penthrox methoxyflurane inhaler approved in an additional 22 European countries

Medical Developments International (MVP) has announced that the Decentralized Procedure for its Penthrox methoxyflurane inhaler marketing application has been completed, and the inhaler has been approved in an additional 22 countries. Penthrox has been available in the UK and Ireland, where it is marketed by Galen, and in Belgium and France, where it is marketed by Mundipharma.

The additional approvals are in Austria, Bulgaria, Croatia, Cyprus, Czech Republic, Denmark, Estonia, Finland, Germany, Iceland, Italy, Latvia, Lithuania, Luxembourg, Norway, Poland, Portugal, Romania, Slovakia, Slovenia, Spain, and Sweden. Mundipharma will market Penthrox in those countries.

MVP CEO John Sharman commented, “The approval of Penthrox for use in Europe is the single biggest achievement in the company’s history. This is a milestone for patients and physicians too: Penthrox can deliver outstanding value against the huge unmet need for fast, easy pain relief for patients who have experienced a trauma injury. By ensuring that a patient’s pain is quickly managed, Penthrox allows healthcare providers to treat the trauma injury faster. This ultimately simplifies the patient journey, helping address the suffering patients experience every day due to under-treatment and inadequate
options for short term relief of moderate and severe trauma pain.”

Mundipharma International Chief Commercial Officer Christian Mazzi said, “This Marketing Authorization is a major step towards bringing Penthrox to people throughout Europe. We’re delighted to be able to continue our proud heritage as leaders in pain management and bring this important new, non-opioid based therapeutic to patients. We look forward to working with the different reimbursement bodies to make sure patients and hospitals have access to Penthrox as soon as possible.”

Read the MVP press release.

Share

published on December 14, 2017

Primary Sidebar

Sign up for our free weekly newsletter

Upcoming Events
Sponsored by Intertek

Want information about upcoming OINDP-related events delivered directly to your inbox? click here

  • June 17-June 18: Rescon Europe 2025, Paris, France
  • June 19-June 20: Metered Dose Inhaler (MDI) Technology Training Course, online
  • June 22-June 25: ISAM Congress 2025, Washington, DC, USA
  • June 25-June 25: SMI.London 2025, London, UK
  • September 18-September 19: IPAC-RS Nasal Innovation Forum, West Trenton, NJ, USA
  • See all upcoming events

    Secondary Sidebar

    Suppliers

    Capsules and blisters
    Consultants
    Contract research
    Contract manufacturing
    Devices
    Education
    Excipients
    Filling equipment
    Instruments
    Particle manufacturing
    Software and modeling
    Solstice Air banner
    © 2025 OINDPnews